These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 6272964

  • 1. T-cell response to B-cells and Epstein-Barr virus antigens in infectious mononucleosis.
    Klein E, Ernberg I, Masucci MG, Szigeti R, Wu YT, Masucci G, Svedmyr E.
    Cancer Res; 1981 Nov; 41(11 Pt 1):4210-5. PubMed ID: 6272964
    [Abstract] [Full Text] [Related]

  • 2. In vitro expansion of Epstein-Barr virus-specific HLA-restricted cytotoxic T cells direct from the blood of infectious mononucleosis patients.
    Strang G, Rickinson AB.
    Immunology; 1987 Dec; 62(4):647-54. PubMed ID: 2828228
    [Abstract] [Full Text] [Related]

  • 3. The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell.
    Thorley-Lawson DA.
    J Immunol; 1980 Feb; 124(2):745-51. PubMed ID: 6243331
    [Abstract] [Full Text] [Related]

  • 4. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
    Dolcetti R, Frisan T, Sjöberg J, De Campos-Lima PO, Pisa P, De Re V, Gloghini A, Rizzo S, Masucci MG, Boiocchi M.
    Cancer Res; 1995 Aug 15; 55(16):3675-81. PubMed ID: 7627978
    [Abstract] [Full Text] [Related]

  • 5. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.
    Adhikary D, Behrends U, Moosmann A, Witter K, Bornkamm GW, Mautner J.
    J Exp Med; 2006 Apr 17; 203(4):995-1006. PubMed ID: 16549597
    [Abstract] [Full Text] [Related]

  • 6. Suppressor T cell clones from patients with acute Epstein-Barr virus-induced infectious mononucleosis.
    Wang F, Blaese RM, Zoon KC, Tosato G.
    J Clin Invest; 1987 Jan 17; 79(1):7-14. PubMed ID: 3025263
    [Abstract] [Full Text] [Related]

  • 7. T cell-mediated immunoregulation of Epstein Barr virus- (EBV) induced B lymphocyte activation in EBV-seropositive and EBV-seronegative individuals.
    Tosato G, Magrath IT, Blaese RM.
    J Immunol; 1982 Feb 17; 128(2):575-9. PubMed ID: 6274959
    [Abstract] [Full Text] [Related]

  • 8. Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis).
    Tosato G, Straus S, Henle W, Pike SE, Blaese RM.
    J Immunol; 1985 May 17; 134(5):3082-8. PubMed ID: 2984282
    [Abstract] [Full Text] [Related]

  • 9. Comparative immunophenotypic features of EBV-positive and EBV-negative atypical lymphocytosis.
    Hudnall SD, Patel J, Schwab H, Martinez J.
    Cytometry B Clin Cytom; 2003 Sep 17; 55(1):22-8. PubMed ID: 12949956
    [Abstract] [Full Text] [Related]

  • 10. Epstein Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis.
    Borysiewicz LK, Haworth SJ, Cohen J, Mundin J, Rickinson A, Sissons JG.
    Q J Med; 1986 Feb 17; 58(226):111-21. PubMed ID: 3012622
    [Abstract] [Full Text] [Related]

  • 11. Defective generation of killer cells against spontaneously Epstein-Barr virus (EBV)-transformed autologous B cells in a fatal EBV infection.
    Yanagisawa M, Kato M, Ikeno K, Kobayashi T, Miyagawa Y, Komiyama A, Akabane T.
    Clin Exp Immunol; 1987 May 17; 68(2):251-8. PubMed ID: 2820633
    [Abstract] [Full Text] [Related]

  • 12. B-cell polyclonal activation and Epstein-Barr viral abortive lytic cycle are two key features in acute infectious mononucleosis.
    Al Tabaa Y, Tuaillon E, Jeziorski E, Ouedraogo DE, Bolloré K, Rubbo PA, Foulongne V, Rodière M, Vendrell JP.
    J Clin Virol; 2011 Sep 17; 52(1):33-7. PubMed ID: 21684200
    [Abstract] [Full Text] [Related]

  • 13. Cell-mediated immunity to Epstein-Barr-virus-transformed lymphoblastoid cells in acute infectious mononucleosis.
    Royston I, Sullivan JL, Periman PO, Perlin E.
    N Engl J Med; 1975 Dec 04; 293(23):1159-63. PubMed ID: 171568
    [Abstract] [Full Text] [Related]

  • 14. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
    Niller HH, Wolf H, Minarovits J.
    Autoimmunity; 2008 May 04; 41(4):298-328. PubMed ID: 18432410
    [Abstract] [Full Text] [Related]

  • 15. The MLC response of patients with infectious mononucleosis to Epstein-Barr virus-transformed cells.
    Wasik M, Myc A, Matej H, Rudzka L.
    Arch Immunol Ther Exp (Warsz); 1983 May 04; 31(6):871-8. PubMed ID: 6331340
    [Abstract] [Full Text] [Related]

  • 16. Regulatory T cell activity in primary and persistent Epstein-Barr virus infection.
    Wingate PJ, McAulay KA, Anthony IC, Crawford DH.
    J Med Virol; 2009 May 04; 81(5):870-7. PubMed ID: 19319950
    [Abstract] [Full Text] [Related]

  • 17. Immune surveillance against Epstein-Barr virus.
    Moss DJ, Burrows SR, Khanna R, Misko IS, Sculley TB.
    Semin Immunol; 1992 Apr 04; 4(2):97-104. PubMed ID: 1377517
    [Abstract] [Full Text] [Related]

  • 18. The effect of tinidazole on primary EBV infection and immunocompetence.
    Marklund G, Ernberg I, Britton S, Lundberg C.
    Scand J Infect Dis; 1984 Apr 04; 16(1):17-23. PubMed ID: 6320359
    [Abstract] [Full Text] [Related]

  • 19. Antibody-dependent cellular cytotoxicity (ADCC) against Epstein-Barr virus-determined membrane antigens. I. Reactivity in sera from normal persons and from patients with acute infectious mononucleosis.
    Jondal M.
    Clin Exp Immunol; 1976 Jul 04; 25(1):1-5. PubMed ID: 186222
    [Abstract] [Full Text] [Related]

  • 20. T-cell control of herpesvirus infections: lessons from the Epstein-Barr virus.
    Rickinson AB.
    Prog Brain Res; 1983 Jul 04; 59():189-202. PubMed ID: 6320264
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.